An Eli Lilly and Company pharmaceutical manufacturing facility is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. Portal/Mike Segar/File Photo Acquire License Rights
Oct 26 (Portal) – Eli Lilly and Co (LLY.N) said on Thursday that the U.S. Food and Drug Administration has approved its drug to treat adults with moderately to severely active ulcerative colitis, a type of chronic inflammatory bowel disease.
The drug, which will be available in the U.S. in the coming weeks and will be sold under the brand name Omvoh, is among Lilly’s potential growth drivers for this decade, along with tirzepatide for obesity, lebrikizumab for atopic dermatitis or eczema and pirtobrutinib for cancer.
The agency’s decision will help Lilly move into a sector where drugs from rivals such as Abbvie Inc (ABBV.N), Pfizer Inc (PFE.N) and Johnson & Johnson (JNJ.N) are already fighting for a share of the multi -Market struggle. Billion dollar market.
The approval was based on data from late-stage trials of the drug that showed it helped improve symptoms of the disease compared with placebo.
The latest approval comes after a setback in April when the U.S. Food and Drug Administration (FDA) rejected the approval, saying there were problems related to the planned manufacturing of the drug.
Lilly received approval for the drug in Japan and the European Union this year.
Ulcerative colitis is a disease in which abnormal immune system responses cause inflammation and ulcers on the inner wall of the colon, potentially leading to diarrhea, blood discharge with stools, and abdominal pain.
Shares of the company rose about 0.5% in extended trading on Thursday.
Reporting by Pratik Jain and Khushi Mandowara in Benagluru; Edited by Anil D’Silva
Our standards: The Trust Principles.
Acquire license rights, opens new tab